Progyny, Inc. (NASDAQ:PGNY) Receives $25.44 Average Price Target from Brokerages

Shares of Progyny, Inc. (NASDAQ:PGNY) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $25.4444.

Several equities analysts recently weighed in on PGNY shares. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Leerink Partners raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 price target on the stock in a research note on Tuesday, July 8th. Truist Financial lifted their price target on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. Raymond James Financial set a $28.00 price target on shares of Progyny in a research note on Friday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th.

Progyny Trading Up 0.3%

NASDAQ:PGNY opened at $18.71 on Friday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 31.71, a PEG ratio of 1.59 and a beta of 1.29. The firm’s fifty day simple moving average is $21.30 and its 200 day simple moving average is $21.93. Progyny has a twelve month low of $13.39 and a twelve month high of $26.76.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). The business had revenue of $332.87 million for the quarter, compared to analyst estimates of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.17 EPS. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, analysts predict that Progyny will post 0.6 earnings per share for the current year.

Insider Buying and Selling at Progyny

In related news, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director owned 12,501 shares of the company’s stock, valued at $275,522.04. The trade was a 16.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the business’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at $1,829,843.12. The trade was a 2.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,895 shares of company stock worth $179,311 in the last ninety days. 9.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Progyny

Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after purchasing an additional 457 shares during the last quarter. New York State Teachers Retirement System increased its position in shares of Progyny by 0.7% in the 1st quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock worth $1,635,000 after purchasing an additional 500 shares during the last quarter. Leibman Financial Services Inc. increased its position in shares of Progyny by 1.1% in the 2nd quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock worth $1,011,000 after purchasing an additional 513 shares during the last quarter. Teza Capital Management LLC increased its position in shares of Progyny by 5.4% in the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after purchasing an additional 516 shares during the last quarter. Finally, Oxford Asset Management LLP increased its position in shares of Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after purchasing an additional 531 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.